Research Article
A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles Using Pathway-Drug Network
Table 11
PageRank of promising drug candidates on the validation network (
).
| Rank | Drug name | Ranking score |
| 1 | Tamoxifen | 0.990 | 2 | Doxorubicin | 0.692 | 3 | Paclitaxel | 0.663 | 4 | Methotrexate | 0.373 | 5 | Fulvestrant | 0.316 | 6 | Camptothecin | 0.257 | 7 | Letrozole | 0.252 | 8 | Vinblastine | 0.235 | 9 | Exemestane | 0.176 | 10 | Aminoglutethimide | 0.108 | 11 | Alsterpaullone | 0.102 | 12 | Megestrol | 0.101 | 13 | MS-275 | 0.088 | 14 | Phenoxybenzamine | 0.080 | 15 | GW-8510 | 0.026 | 16 | Celastrol | 0.023 | 17 | Tyrphostin_AG-825 | 0.010 |
|
|
Known breast cancer drug. Potential drug candidate for repositioning.
|